Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia

BACKGROUND: The recent approval of innovative therapies for spinal muscular atrophy (SMA), such as nusinersen, has brought hope to patients and their families. OBJECTIVE: The aims of this study were to compare the characteristics and HRQoL of SMA patients treated with nusinersen and those treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: AlRuthia, Yazed, Almuaythir, Ghadah S, H Alrasheed, Hala, Alsharif, Wejdan R, Temsah, Mohamad-Hani, Alsohime, Fahad, Sales, Ibrahim, Alwhaibi, Monira, Bashiri, Fahad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053517/
https://www.ncbi.nlm.nih.gov/pubmed/33880016
http://dx.doi.org/10.2147/PPA.S305849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053517/
https://www.ncbi.nlm.nih.gov/pubmed/33880016
http://dx.doi.org/10.2147/PPA.S305849

Ejemplares similares